 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| IP2015 / Initiator Pharma, pregabalin / Generic mfg.
In the pain challenge few months ago vs @pfizer #pregabalin or #lyrica IP2015 statistically significant effect on Allodynia (Trigeminal Neuralgia, Migraine etc) and showed dose dependent effects on the measures pain parameters. Not much left in the pain segment. $30m mcap. (Twitter) - Feb 4, 2023
- |||| IP2015 / Initiator Pharma, pregabalin / Generic mfg., duloxetine / Generic mfg.
Clinical: $INIT IP2015 superior to Duloxetin (Cymbalta) @LillyPad in both safety and efficiency. Right now undergoing fas1b pain study (indication = trigeminal Neuralgia) and benching against Pregabalin (Lyrica) @pfizer . Could be a game-changer. Results in the next 3-5 weeks (Twitter) - May 3, 2022
- || IP2015 / Initiator Pharma
New P1 trial: Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model (clinicaltrials.gov) - Jan 6, 2022
P1, N=24, Not yet recruiting, Sponsor: Initiator Pharma